3. INTRODUCTION
Hemophilia A is a genetic bleeding disorder in which an individual lacks
or has low levels of proteins named clotting factor VIII. The mainstay
treatment option has long been FVIII replacement therapy. Initially,
FVIII replacement was accomplished by donated whole blood,
subsequently by plasma and currently by recombinant human FVIII
(rFVIII) replacement therapies, which revolutionized the treatment of
Hemophilia A.
4. Hemophilia A is a general term for a group of rare bleeding disorders caused by a
congenital deficiency of certain clotting factors. The main form of hemophilia is
hemophilia A; it is different from Hemophilia B.
The main difference between them is that Hemophilia B is associated with
deficiency in factor IX (9) while Hemophilia A is associated with deficiency of factor
VIII. More than 80% of people with hemophilia have hemophilia A.
WHAT IS HEMOPHILIA-A?
6. ● The total prevalent population of Hemophilia A in the 7MM in 2017 was 42,458 and
expected to rise by 2030
● Severe Hemophilia A cases are more prominent in comparison to mild and
moderate. Additionally, moderate and severe accounts for 75% of the Hemophilia A
patient pool.
● According to DelveInsight’s analysis, the highest prevalent population of Hemophilia
A is in the United States with 14,200 cases in 2017.
● Around 30% of severe Hemophilia A cases develop inhibitors against the
replacement factor VIII
Read Here
7. Hemophilia an is an x-connected draining issue brought about by insufficiency or
complete shortfall of coagulation factor VIII (hemophilia A) or factor IX
(hemophilia B). Bleeding in hemophilia happens because of the disappointment
of auxiliary hemostasis. Essential hemostasis and the development of platelet
plug happens typically, yet adjustment of the attachment by fibrin is blemished
in light of the age of deficient measures of thrombin.
HEMOPHILIA-A PATHOGENESIS
09
8. 1. Unexplained and over the top seeping from cuts or wounds or
after a medical procedure or dental work.
2. Numerous enormous or profound wounds.
3. Uncommon seeping after immunizations.
4. Agony, growing, or snugness in your joints.
5. Blood in your pee or stool.
6. Nosebleeds without a known reason.
7. In newborn children, unexplained crabbiness.
HEMOPHILIA-A SYMPTOMS
9. Hemophilia A is a life-long condition. Currently, there is no cure, but researchers are actively
engaged in finding the cure through gene therapy. One hope is that by inserting a healthy version of
the defective blood factor gene, a person with hemophilia will be able to produce reasonable
amounts of a factor on their own.
Generally, Hemophilia A patients are provided with “On Demand” and “Prophylaxis” treatment. But
Prophylaxis treatment option has gained importance in comparison to the on-demand treatment
options.
Currently, the major treatment options of Hemophilia A are Factor Replacement Concentrates, the
source of which is either recombinant DNA technology or Human plasma-derive, and Bypassing
agents. Moreover, this is an off-label treatment option, wherein Desmopressin Acetate (DDAVP) and
Adjunctive therapies are also available for the management of Hemophilia A.
HEMOPHILIA-A TREATMENT
11. SWOT ANALYSIS
Premium-priced agents dominate the hemophilia A
Market. Being an orphan indication it can get
accelerated approval time, seven year of market
exclusivity, clinical trials subsidies and reduced
regulatory fees, among others
Many options are available in recombinant factor
VIII and this approach is expected to be more
crowded in future, ultimately impacting uptake of
new drugs with same approach
Very limited treatment options are available in severe
segment, thus, providing lucrative market
Opportunities. Rising prevalence of hemophilia A will
provide larger window of opportunity for new
treatments
Cost of treatment of hemophilia A is very high and the
upcoming treatment options like gene therapies and
extended half-life products are also expected to be in
higher side and healthcare authorities will seek to restrict
pricing and usage of high cost agent.
HEMOPHILIA-A
S
O T
W
12. HEMOPHILIA-A MARKET REPORT SCOPE
1. The Hemophilia A report covers the descriptive overview of Hemophilia A, explaining its
causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
2. Comprehensive insight has been provided into the Hemophilia A epidemiology and
treatment in the 7MM
3. Additionally, an all-inclusive account of both the current and emerging therapies for
Hemophilia A are provided, along with the assessment of new therapies, which will have an
impact on the current treatment landscape
4. A detailed review of Hemophilia A market; historical and forecasted is included in the
report, covering drug outreach in the 7MM
5. The report provides an edge while developing business strategies, by understanding
trends shaping and driving the global Hemophilia A market
14. ABOUT DELVEINSIGHT
DelveInsight is a premier Business Consulting and Market Research firm that is involved in preparation of market
research reports and analysis by in-house & external experts on pharmaceutical & biotech products, covering
developed & emerging markets, for Pharma, biotech & marketing companies, in the healthcare & medical device
industries. We are an one-stop destination for individuals, research institutions and companies seeking strategic
advice and direction, as we provide global, regional and country-specific market research studies in the
pharmaceutical and healthcare domain. DelveInsight has a purview of 3000+ market research reports, encompassing
nearly every market category that will keep you up-to-date about the present and future market trends with
competitive analysis of existing or emerging products & strategies. Our tactical guidance helps our clients stay ahead
of the competition. Our research model is a unique mix of data analytics and market research methodology to help
businesses achieve optimal performance.
